AI / ML Innovations Stock Price, News & Analysis

AIML (OTCQB:AIMLF) announced on October 15, 2025 that its subsidiary NeuralCloud Solutions is launching a pilot of CardioYield with Heartdent Center in Kingston, Jamaica.

The feasibility study will pair a single-lead ECG wearable chest strap with CardioYield's AI Holter-reporting and ECG analysis to test workflow integration, operational impact, and a low-cost, scalable diagnostic model aimed at expanding access to cardiac care in Jamaica.

The pilot seeks to validate clinical workflow, improve affordability and reduce wait times for diagnostics in a country where cardiovascular disease accounts for about one-third of deaths.

AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) announced that its subsidiary NeuralCloud Solutions is launching a pilot with the Toronto Heart Centre to evaluate CardioYield™, the company's AI visualization and reporting interface powered by MaxYield™. The study will compare Holter ECG reporting workflows, measuring technician efficiency, report turnaround time, and analysis quality versus current industry-standard software.

The release describes CardioYield™ features including automated removal of baseline wander and motion artifacts, beat-level PQRST labeling with interval calculations, and a unified reporting interface intended to reduce repetitive corrections and analyst fatigue. Management and clinical leaders framed the pilot as a step to quantify efficiency and diagnostic reliability in real-world practice.

AI/ML Innovations (OTCQB:AIMLF) has announced a strategic pilot project between its subsidiary Neural Cloud Solutions and the BC Brain Wellness Program (BCBWP). The collaboration will utilize Neural Cloud's MaxYield ECG technology to study the heart-brain connection in patients with neurological conditions.

The pilot represents the first deployment of MaxYield, an AI-driven ECG signal-enhancement engine, in a neurology-focused exercise program. The technology will analyze physiological data from individuals with conditions like Parkinson's disease, stroke, and multiple sclerosis during supervised exercise settings to understand how cardiac responses may correlate with neurological status and outcomes.

This initiative aims to verify the algorithm's performance in real-world settings and establish groundwork for future research collaborations, focusing on condition-specific cardiac responses and potential HR/HRV biomarkers.

AI/ML Innovations (OTCQB:AIMLF) has successfully completed an oversubscribed non-brokered private placement, raising $2,128,595 through the issuance of 42,571,900 Units at $0.05 per Unit. Each Unit includes one common share and one warrant exercisable at $0.15 until September 22, 2030.

Notable insider participation included CEO Paul Duffy (5M Units), President Peter Kendall (500K Units), CPO Esmatullah Naikyar (120K Units), and major shareholder Sheldon Inwentash (26M Units). Additionally, the company extended the expiry date of 12,376,666 December 2023 Warrants to December 19, 2028, and granted 5,700,000 stock options to officers, employees, and consultants at $0.10 per share.

AI/ML Innovations (OTCQB:AIMLF) has announced plans for a non-brokered private placement offering of up to 31,000,000 units at $0.05 per unit, aiming to raise gross proceeds of up to $1.55 million.

Each unit consists of one common share and one warrant, with each warrant exercisable at $0.15 per share for a five-year term. The securities will have a four-month and one-day hold period. The company plans to use the proceeds for working capital requirements and will pay finder's fees to qualified finders. The private placement remains subject to necessary approvals, including from the Canadian Securities Exchange.

AI/ML Innovations (OTCQB:AIMLF) has filed an amended and restated management's discussion and analysis (MD&A) for the periods ending January 31, 2025, following a review by the British Columbia Securities Commission. The amended filing addresses several disclosure deficiencies.

The enhanced disclosure includes details about new strategic initiatives, R&D activities, operational results, and the acquisition of Quantum Sciences Ltd. Additional information covers related party payments, an exit agreement with Tech2Heal, and other minor updates. The complete Amended MD&A is accessible on SEDAR+.

AI/ML Innovations (OTCQB:AIMLF) has announced the completion of its restructuring related to the previously acquired Quantum Sciences Ltd. The restructuring, which follows the original acquisition from December 23, 2024, includes key modifications to the initially announced terms.

Two notable changes from the original restructuring announcement include: (1) the non-execution of a planned reseller agreement with Mark Orsmond, and (2) the retention of all intellectual property rights and interests in the "meApp" application by AIML, rather than transferring them to Mark Orsmond as previously planned.

AI/ML Innovations (AIML) has strengthened its intellectual property portfolio by filing provisional patent applications with the USPTO through its subsidiary Neural Cloud Solutions. The patents cover advanced neural network architectures and cloud-based ECG signal optimization workflows, specifically protecting their MaxYield and CardioYield platforms. The technology includes AI-driven ECG signal processing, cloud-native workflows, and a dynamic reporting engine that supports clinical workflows. The patent filings aim to protect both algorithmic foundations and deployment infrastructure, positioning AIML strategically in the AI-assisted cardiology market. The company's CardioYield system enables structured outputs including rhythm classifications, interval measurements, and reviewable event flags, designed to enhance clinician review across various clinical contexts.

AI/ML Innovations' subsidiary Neural Cloud Solutions has signed a Letter of Intent with Circular Health Limited to integrate and license its MaxYield™ ECG signal-processing platform. The partnership will enhance Circular Health's smart ring device with improved ECG signal clarity through a cloud-based API integration. The agreement includes a per-user SaaS licensing model, with commercial launch targeted for September 2025. MaxYield™ is expected to provide higher data yield, scalable workflow, and enable expansion into medical markets as it progresses through FDA 510(k) clearance. The technology will allow Circular Health to capture more usable data, enhance measurement precision, and redeploy resources from signal cleaning to advanced analytics and patient engagement.